#aaf? ,,congress  #b;d ,session  ,s4    
#dfab  ,,an ,,act  ,to designate        
me?amphetam9e z an em]g+ ?reat1 & = o!r 
purposes4  #a4 ,%ort title ,?is ,act may
 be cit$ z ! ,me?amphetam9e ,response   
,act ( #bjbj4  #b4 ,f9d+s ,congress f9ds
 ! foll[+3 7#a7 ,me?amphetam9e poses a  
significant public heal? & safety ?reat 
& qualifies z an em]g+ drug ?reat1 z    
def9$ 9 section #gjb ( ! ,(fice (       
,national ,drug ,control ,policy        
,reau?orization ,act ( #aiih 7#ba       
,u4,s4,c4 #agja74  7#b7 ,me?amphetam9e  
treatm5t admissions increas$ f #ae4a    
p]c5t ( all admissions 9 #bjjh to #bc4f 
p]c5t 9 #bjag1 ! late/ ye> = :i* data is
 available4  7#c7 ,dur+ ! timeframe     
describ$ 9 p>agraph 7#b7-- 7,a7         
me?amphetam9e-relat$ treatm5t admissions
 among wom5 increas$ f #ai4b p]c5t ( all
 drug-relat$ treatm5t admissions to     
#bh4c p]c5t2 &  7,b7 h]o9 use among ^?  
admitt$ = me?amphetam9e-relat$ treatm5t 
increas$ f #e4c p]c5t to #bc4f p]c5t4   
7#d7 ,by ! end ( #bjai1 me?amphetam9e   

availability1 use1 purity1 & pot5cy _h  
increas$ nationally1 z /reet-level      
prices decl9$4  7#e7 ,me?amphetam9e use 
is a nationwide issue4 ,its use rema9s  
widespread 9 ,midwe/ & ,we/]n ,/ates &  
is becom+ increas+ly preval5t 9         
,nor!a/]n ,/ates4  7#f7 ,me?amphetam9e  
is ! drug mo/ (t5 associat$ ) viol5t    
crime4  7#g7 ,accord+ to ! ,c5t]s =     
,disease ,control & ,prev5tion-- 7,a7   
betwe5 #bjah & #bjai1 drug ov]dose dea?s
 involv+ me?amphetam9e & o!r /imulants  
increas$ by #bg p]c5t nationally2  7,b7 
! numb] ( dea?s describ$ 9 subp>agraph  
7,a7 increas$ 9 #bg ( ! #ch ,/ates t    
provide drug-specific ov]dose data to ! 
,c5t]s = ,disease ,control & ,prev5tion2
 &  7,c7 betwe5 ,janu>y #bjai & ,janu>y 
#bjbj1 among #cf ,/ates & ! ,di/rict (  
,columbia1 suspect$ /imulant ov]doses1  
includ+ me?amphetam9e1 treat$ 9 em]g5cy 
dep>tm5ts increas$ by #bc p]c5t4  7#h7  
,me?amphetam9e-relat$ ov]dose dea?s w   
likely cont9ue to increase 9 #bjbj1 due 
9 "p to ! ongo+ ,,covid-#ai p&emic1 :i* 

makes obta9+ treatm5t = sub/ance use    
disord]s1 includ+ me?amphetam9e use1 m  
difficult4  7#i7 ,! increase 9          
me?amphetam9e use & ! negative          
respiratory & pulmon>y heal? effects    
associat$ ) its use has caus$ !         
,national ,in/itute on ,drug ,abuse to  
w>n cl9icians to be prep>$ to monitor   
adv]se effects :5 treat+ individuals us+
 me?amphetam9e :o also h ,,covid-#ai4   
7#aj7 ,s9ce ! onset ( ,,covid-#ai 9 !   
,unit$ ,/ates1 ! numb] ( law en=cem5t & 
fir/ respond] ag5cies ent]+ data into   
nationwide ov]dose mapp+ applications to
 track real-"t suspect$ ov]doses1       
includ+ me?amphetam9e ov]doses1 has     
increas$4  7#aa7 ,9 ! fir/ #i mon?s (   
fiscal ye> #bjbj1 !re 0 a #eb p]c5t     
increase 9 ! am\nt ( me?amphetam9e seiz$
 by ,u4,s4 ,cu/oms & ,bord] ,protection4
  7#ab7 ,public reports indicate t      
,mexican c>tels may be /ockpil+ money & 
illicit drugs1 includ+ me?amphetam9e1 on
 bo? sides ( ! ,s\?we/ ,bord] & t !     
,drug ,en=cem5t ,adm9i/ration is prep>+ 

to respond to any pot5tial surge 9      
supply4  7#ac7 ,int5tional prep>ation to
 c\nt] any surges 9 production1         
di/ribution1 & use are ess5tial 9 l[]+  
me?amphetam9e-relat$ ov]dose dea?s &    
sub/ance use disord]s4  #c4 ,decl>ation 
( em]g+ ?reat  7a7 ,9 g5]al ,congress   
decl>es me?amphetam9e an em]g+ drug     
?reat1 z def9$ 9 section #gjb ( ! ,(fice
 ( ,national ,drug ,control ,policy     
,reau?orization ,act ( #aiih 7#ba       
,u4,s4,c4 #agja71 9 ! ,unit$ ,/ates4    
7b7 ,requir$ em]g+ ?reat response plan  
,n lat] ?an #ij days aft] ! date (      
enactm5t ( ?is ,act1 ! ,director ( !    
,(fice ( ,national ,drug ,control       
,policy %all e/abli% & implem5t an      
,em]g+ ,?reat ,response ,plan t is      
specific to me?amphetam9e 9 accordance )
 section #gji7;d7 ( ! ,(fice ( ,national
 ,drug ,control ,policy ,reau?orization 
,act ( #aiih 7#ba ,u4,s4,c4 #agjh7;d774 
,pass$ ! ,s5ate ,novemb] #af1           
#bjbj4,secret>y